

**12th Congress of the World Federation of Nuclear Medicine
and Biology**

20-24 April 2018

TRACK: ONCOLOGY

Melbourne Convention and Exhibition Centre

Saturday 21 April 2018

10:30-12:00	ONCOLOGY 1- PROSTATE CANCER		Time
	Chair: A/Prof Hossein Jadvar & Prof Michael Hofman		
10:30-11:00	Surgeon's Perspective: Imaging and Treating Primary Prostate Cancer Learning Objectives: 1. To provide an overview of best practice in the clinical management of prostate cancer patients 2. To discuss implications of staging and management of prostate cancer 3. To discuss the roles of nuclear medicine in the standard management of primary prostate cancer.	Prof Declan Murphy, Peter MacCallum Cancer Centre, Melbourne, Australia	30 mins
11:00-11:30	PET/CT and PET/MRI in Prostate and Urological Malignancy Learning objectives. 1. Evaluate the evidence and mechanisms of uptake for PET CT and PET MRI in prostate and other urologic malignancies. 2. Determine relative value of FDG, PSMA, Choline and MRI in prostate cancer in particular and comparative evidence for the molecular tracers at different stages of disease. 3. Evaluate synergistic value of combined imaging both in the staging setting and in biochemical failure.	A/Prof Louise Emmett, St Vincent's Hospital, Sydney, Australia	30 mins
11:30-12:00	The Power of Precision Oncology: Improved Overall Survival after 5 Years of PSMA Radioligand Therapy in >200 Prostate Cancer Patients Learning Objectives: 1. To understand precision oncology in urological malignancy 2. Understand the application of PSMA radioligand therapy and the treatment outcomes achieved.	Prof Richard Baum, Zentralklinik, Bad Berka, Germany	30 mins
1615 - 1745	ONCOLOGY 2: NEUROENDOCRINE CARCINOMA		
	Chair: Prof Richard Baum & Dr David Pattison		
16:15-16:45	A Clinical Overview of Neuroendocrine Tumours Learning objectives: 1) To understand the heterogeneity inherent in NETs 2) To describe the challenges in diagnosing NETs and the modalities used 3) To discuss classes of treatment for NETs and when each one would be considered.	Dr. David Chan, Royal North Shore Hospital, Sydney, Australia	30 mins
16:45-17:15	The Role of PET imaging in Neuroendocrine Tumours Educational objectives: 1. To describe normal patterns, pearls and pitfalls in interpretation of 68Ga-DOTATATE PET/CT 2. To discuss the clinical diagnostic utility of PET imaging in neuroendocrine tumours 3. The role of PET imaging in theranostics/treatment planning.	Dr Grace Kong, Peter MacCallum Cancer Centre, Melbourne, Australia	30 mins
17:15-17:45	Theranostics of Neuroendocrine Neoplasms – Past, Present and Future of PRRT Learning objectives: 1. Personalized medicine and precision oncology in the era of Theranostics. 2. The importance of molecular imaging with PET/CT in the selection of patients for peptide receptor radionuclide therapy (PRRT) and post-PRRT follow-up. 3. PRRT of neuroendocrine neoplasms (NEN) a. Results of intention to treat analysis of 1048 patients treated with PRRT at Zentralklinik Bad Berka b. Results of the randomised controlled trial - NETTER-1 4. Future prospects of PRRT a. New radionuclides and peptides b. New treatment combinations.	Dr Aviral Singh, Zentralklinik, Bad Berka, , Germany	30 mins

Saturday 21 April 2018 cont.

1615 - 1745	ONCOLOGY 3: GYNAECOLOGICAL CARCINOMA		
	Chair: Prof Wim Oyen & Prof Michael McKay		
16:15-16:45	Gynaecological Cancers: Value of PET/MR and non-FDG Tracers Learning objectives: 1. To understand how PET/MR may add value in gynaecological cancers 2. To learn how non-FDG tracers may be of value in gynaecological cancers.	Prof. Andreas Kjaer, Univeristy of Copenhagen, Denmark	30 mins
16:45-17:15	PET/CT and PET/MRI in Gynaecological Carcinoma At the conclusion of this CME activity, the learner should be better able to: 1. Understand the role of FDG PET/CT for staging of cervix cancer and ovarian cancer and why it is a clinically valuable supplement for the FIGO classification. 2. Understand the usefulness of FDG PET/CT in planning of radiotherapy for treatment of cervix cancer and for deciding the treatment for ovarian cancer. 3. Acknowledge the draw backs of FDG PET/CT in oncology. 4. Discuss the possible applications for PET/MRI in gynecological carcinoma.	Dr. Annika Loft - Dept. of Clin.Phys., Nucl.Med. & PET, Copenhagen Denmark	30 mins
17:15-17:45	Sentinel Lymphoscintigraphy in Gynaecological Carcinoma Learning Objectives 1. Analyse the current situation (guidelines), 2. Illustrate the methods employed, 3. Explore the future directions.	Prof Francesco Giammarile, IAEA, Austria	30 mins

SUNDAY 22 April 2018

10:30-12:00 ONCOLOGY 4: HEAD & NECK CARCINOMA			
Chair: Dr John Koutsikos & A/Prof Paul Thomas			
10:30-11:00	<p>Overview: An oncologist approach to the Management of Head and Neck Cancer For learning objectives</p> <ol style="list-style-type: none"> 1. To provide an overview of best practice in the clinical management of head and neck cancer patients 2. To discuss current controversies in the management of head and neck cancer patients 3. To discuss the roles of nuclear medicine in the standard management and also in areas of controversies in head and neck cancer. 	A/Prof. Hui Gan Austin Health & Olivia Newton-John Cancer Research Institute, Melbourne, Australia	30 mins
11:00-11:30	<p>Read with the Experts: SPECT/CT lymphoscintigraphy & PET/CT in Head & Neck Cancer Learning Objectives:</p> <ol style="list-style-type: none"> 1. To review common head and neck cancers with PET/CT 2. To review the head and neck lymphoscintigraphy with SPECT/CT. 	Prof Rathan Subramaniam, University Texas South Western, USA	30 mins
11:30-12:00	<p>The Contribution of Molecular Imaging to Radiotherapy Planning and Response Evaluation in Head and Neck Cancer Learning Objectives:</p> <ol style="list-style-type: none"> 1. To understand how PET/CT can be incorporated in treatment planning in head & neck cancer patients 2. To Review technical aspects of acquiring PET/CT for use in radiotherapy treatment planning 3. To review the role of molecular imaging in evaluating response to radiotherapy in head & neck cancer patients 	Prof Michael McKay Austin Health & La Trobe University, Melbourne, Australia	30 mins
1400 - 1530 ONCOLOGY 5: NEURO-ONCOLOGY			
Chair: Prof Andreas Fotopoulos & Dr Geoff Schrembri			
14:00-14:30	<p>Current Practise and Controversies in Neuro-Oncology Learning objectives</p> <ol style="list-style-type: none"> 1) To provide an overview of best practice in the clinical management of neuro-oncology patients 2) To discuss current controversies in the management of neuro-oncology patients 3) To discuss the roles of nuclear medicine in the standard management and also in areas of controversies. 	A/Prof. Hui Gan, Austin Health & Olivia Newton-John Cancer Research Institute, Melbourne, Australia	30 mins
14:30-15:00	<p>Read with the Experts: PET in Neuro-Oncology Learning objectives:</p> <ol style="list-style-type: none"> 1. To discuss the potential and the challenges of imaging in Neuro-Oncology. 2. To provide an overview of PET tracers in Neuro-Oncology, with a focus on amino acid PET imaging. 3. To identify areas of future research and development. 	Prof Dr Roslyn Francis, University of Western Australia, Perth Australia	30 mins
15:00-15:30	<p>Neuro-oncology-Treat with The Experts Learning Objectives</p> <ol style="list-style-type: none"> 1. The principle of Boron Neutron Capture Therapy (BNCT) 2. How to deliver boron-10 specifically to cancer 3. The role of PET-CT in BNCT. 	Prof. Jun Hatazawa, Osaka University Graduate School of Medicine, Osaka, Japan	30 mins

Monday 23 April 2018

10:30-12:00 ONCOLOGY 6: LYMPHOMA			
Chair: Prof Homer Macapinlac & Dr Paul Roach			
10:30-11:00	Overview of Lymphoma from a Clinician's Perspective Learning objectives 1. To provide an overview of best practice in the clinical management of lymphoma patients 2. To discuss current controversies in the management of lymphoma patients 3. To discuss the roles of nuclear medicine in the standard management and also in areas of controversies in lymphoma.	Prof John Seymour , Peter MacCallum Cancer Centre, Melbourne, Australia	30 mins
11:00-11:30	FDG-PET/CT for Assessment of Treatment Response in Lymphoma Intended learning objectives : 1. List the evidence-based indications for FDG-PET/CT-based assessment of response in treatment of lymphoma 2. Apply FDG-PET/CT criteria for assessment of response in treatment of lymphoma 3. Have knowledge of the pitfalls and limitations of FDG-PET/CT-based assessment of response in treatment of lymphoma.	Prof. Wim Oyen, The Institute of Cancer Research, Sutton, UK	30 mins
11:30-12:00	Radioimmunotherapy of Lymphoma: Past, Present and Future Learning Objectives: 1. Review clinical experience with treatment of NHL and HD with Radioimmunotherapy at non-myeloablative doses as a salvage, consolidation, and as initial primary treatment. 2. Review clinical experience with dosimetry-driven (planar and SPECT) RIT at myeloablative doses for recurrent disease. 3. Examine the potential roles of next generation radioimmunotherapies with fully human antibodies and alternative radioisotopes.	Prof. Richard Wahl, Washington University in St Louis School of Medicine, USA	30 mins
1400 - 1530 ONCOLOGY 7: LUNG CARCINOMA			
Chair: Dr Ben Greenspan & Dr Salvatore Berlangieri			
14:00-14:30	Management of NSCLC in the Age of Immunotherapy Learning Objectives: 1. -understand implications of staging and management of NSCLC 2. -immunotherapy applications in NSCLC 3. -imaging modalities and response to immunotherapies.	A/Prof. Tom John, Austin Health & Olivia Newton-John Cancer Research Institute, Melbourne, Australia	30 mins
14:30-15:00	FDG PET/CT in Lung Cancer Learning Objectives: 1. -understand the role of FDG PET/CT in the staging of lung cancer 2. Understand the advantages and limitations of FDG PET/CT in the assessment of lung cancer 3. Appreciate the potential pitfalls in the interpretation of FDG PET/CT in lung cancer.	Prof Dr Eddie Lau, Austin Health, Melbourne, Australia	30 mins
15:00-15:30	Role of PET/CT in Curative -Intent Treatment of Lung Cancer with Radiotherapy Learning Objectives : 1. Central role of PET/CT in selecting patients for curative intent radiotherapy/chemoradiotherapy 2. How to use PET/CT for target volume definition 3. Potential roles of tracers other than FLT.	Prof. Michael MacManus, Peter MacCallum Cancer Centre, Melbourne, Australia	30 mins

Monday 23 April 2018 cont.

1615 - 1745	ONCOLOGY 8: THERANOSTICS		
	Chair: Prof Sam Gambhir & Prof Rod Hicks		
16:15-16:45	Molecular Imaging for Oncology Drug Development Learning Objectives 1. What is a "theranostic" drug, and what role does this concept play in drug development? 2. A theranostic is a drug moiety with both diagnostic and therapeutic applications. In regard to radioactive drugs such as radio antibodies and antibody forms, quantitative molecular imaging will provide information on dosimetry in terms of the ability of selective targeting to tumors to achieve potentially therapeutic levels of radiation, with acceptable toxicity. 3. What are other examples of Molecular Imaging applications in drug development? a) Nanoparticles as drug carriers with effectiveness monitored by PET imaging: b) TKI inhibitor drugs to overcome RAI resistance by the re-induction of radio iodine uptake in thyroid cancer c) Evaluation of heterogeneity of expression of the androgen receptor as a target for selective inhibitor drugs in advanced prostate cancer.	Dr Steven Larson, Memorial Sloan Kettering Cancer Centre, New York, USA	30 mins
16:45-17:15	Creating Probes for Theranostics Learning Objectives 1. To understand the process of bench-to bedside translation of new molecular imaging agents 2. To provide an example of successful development and evaluation of molecular imaging agents.	Dr. Andrei Iagaru, Stanford University Medical Centre, USA	30 mins
17:15-17:45	Theranostics Overview of Prostate Carcinoma Learning Objectives 1) To review the natural history of prostate cancer and relevance of imaging at various phases of the disease. 2) To summarize the utility and limitations of several PET radiotracers in the imaging evaluation of prostate cancer. 3) To define theranostics and its evolving role in management of prostate cancer.	A/Prof. Hossein Jadvar, University of Southern California, Los Angeles USA	30 mins

Tuesday 24 April 2018

10:30-12:00	ONCOLOGY 9: COLORECTAL CARCINOMA		
	Chair: Dr Partha Choudhury & Dr Eva Wegner		
	Overview of Colorectal Carcinoma from a Clinician's Perspective Learning objectives 1. To provide an overview of best practice in the clinical management of colorectal cancer patients 2. To discuss current controversies in the management of colorectal cancer patients 3. To discuss the roles of nuclear medicine in the standard management and also in areas of controversies in colorectal cancer.		
10:30-11:00		Prof. Alexander Heriot, Peter MacCallum Cancer Centre, Melbourne, Australia	30 mins
	Read with the Experts: Hepatic Metastases in Colorectal Cancer Title : Read with the Experts: Hepatic metastases Learning Objectives: 1) Understand the role of multimodality imaging in work-up of locoregional therapy of colorectal cancer liver metastasis 2) Understand the use of FDG PET/CT for evaluating chemosensitivity of colorectal cancer liver metastases 3) Opportunity and limits of the use of MAA SPECT-CT for pre-SIRT dosimetry and response prediction.		
11:00-11:30		Prof Patrick Flamen, Jules Bourdet Institute, Brussels, Belgium	30 mins
	Treat with the Experts –Regional treatment with 90Y-SiRsphere Learning Objectives: 1. To understand the concept of radioembolization with SIRT. 2. To understand how regional treatment with 90Y-SiRsphere is utilized in colorectal cancer patients 3. To Review technical aspects of regional treatment with 90Y-SiRsphere treatment		
11:30-12:00		Dr Elizabeth Bernard, Royal North Shore Hospital, Sydney, Australia	30 mins
1400 - 1530	ONCOLOGY 10: BREAST CARCINOMA		
	Chair: Dr Kristoff Muylle & Sze Ting Lee		
	Overview of Breast Cancer from a Clinician's Perspective Learning Objectives: 1. To provide an overview of best practice in the clinical management of breast cancer patients 2. To discuss implications of staging and management of breast cancer 3. To discuss the roles of nuclear medicine in the standard management of breast cancer.		
13:00-13:30		Prof Shereen Loi, Peter MacCallum Cancer Centre, Melbourne, Australia	30 mins
	Read with the Experts: PET/CT in Breast Carcinoma Learning objectives: 1. To describe normal patterns, pearls and pitfalls in interpretation of PET/CT in breast cancer 2. To discuss the clinical diagnostic utility of PET /CT imaging in breast cancer 3. The role of PET imaging in theranostics/treatment planning.		
13:30-14:00		Prof Enrique Estrada Lobato, IAEA Vienna Austria	30 mins
	Sentinel Lymphoscintigraphy in Breast Carcinoma Learning Objectives 1. Analyse the current situation (guidelines), 2. Illustrate the methods employed, 3. Explore the future directions.		
14:00-14:30		Dr Francesco Giammarile, IAEA, Austria	30 mins
1615 - 1745	ONCOLOGY 11: HEPATOBILARY & GASTRIC CARCINOMA		
	Chair: Prof John Buscombe & Dr Gabriella Cehic		
	Clinical Utility of FDG-PET/CT in Gastric Cancer Learning objectives: 1. To review the characteristics of gastric cancer 2. To learn clinical utility and limitation of FDG-PET in diagnostic imaging of gastric cancer		
15:15-15:45		Prof Dr Yuji Nakamoto, Kyoto University, Japan	30 mins
	C-11 acetate and F-18 FDG PET/CT for Hepatocellular Carcinoma (HCC) Research Learning objects 1. Prognostic value of F-18 FDG PET/CT in HCC patients: the results of KSNM (Korean society of nuclear medicine) CTN (clinical trials network) research 2. Difference in diagnostic accuracy between C-11 acetate and F-18 FDG PET/CT through understanding of tumor microenvironment.		
15:45-16:15		Dr Seong Yeong Kwon, Chonnam National University Hwasun Hospital, Jeonnam, Korea	30 mins
	Role of MRI in the Treatment of Hepatocellular & Gastric Cancer with Radiotherapy Learning Objectives: 1. Central role of PET/MRI in selecting patients for curative intent radiotherapy/chemoradiotherapy 2. How to use PET/MRI for target volume definition.		
16:15-16:45		Prof. Mark Goodwin , Austin Health, Melbourne, Australia	30 mins